T. Rowe Price Group, Inc. · NASDAQ:TROW
T. Rowe Price — Investor Presentation (April 2024)
34 slides from T. Rowe Price's investor presentation, April 2024
Slide 1: US Large Cap Growth & US All-Cap Opportunities
Join the conversation: LinkedIn: @TRowePriceUK #USEquities US Large Cap Growth & US All-Cap Opportunities Julian Cook, Portfolio Specialist THIS MARKETING COMMUNICATION IS FOR INVESTMENT PROFESSIONALS ONLY. NOT FOR RETAIL DISTRIBUTION.
Slide 2: Investment Ideas in US Equities: US Large-Cap Growth
Investment Ideas in US Equities: US Large-Cap Growth Julian Cook Portfolio Specialist T. R O W E P R I C E 2
Slide 3: Global Market Environment—Market Outlook
Global Market Environment—Market Outlook As of 31 March 2024 Positives Negatives ▪ Economic growth remains strong ▪ Disinflation trend has stalled ▪ Artificial intelligence driving growth ▪ Services and energy inflation risks ▪ Low corporate & consumer leverage ▪ Significant equity market concentrat
Slide 4: Major Considerations for US Equity Investing
Major Considerations for US Equity Investing Dominance of Outlook for US Magnificent 7 Earnings Investing in Artificial Identifying Intelligence opportunities T. R O W E P R I C E 4
Slide 5: US equity market styles diverging – soft landing, lower rates or both?
US equity market styles diverging – soft landing, lower rates or both? 31 December 2019 to 29 March 2024 Relative Performance: Small Cap vs. Large Cap / Value vs. Growth 30 Russell 1000 Value less Russell 1000 Growth (Value vs Growth) 20 Russell 2000 less Russell 1000 (Small vs Large) 10 0 -10 ‘High
Slide 6: Significant Performance Impact of Mag-7
Significant Performance Impact of Mag-7 As of 31 March 2024 Magnificent 7 Have Driven MSCI All-Country World Index Returns … stocks accounted for 25% Cumulative Change Magnificent 7 20% 15% 10% Rest of Index Total 31% 5% of total index1 return 1 year 0% through 31 March 2024 -5% Mar-23 May-23 Jul-23
Slide 7: Mag-7 stocks have affected broad market valuations
Mag-7 stocks have affected broad market valuations 15 Years Ending 31 March 2024 50x Difference Between Magnificent 7 PE and rest of S&P 500 45x Magnificent 7* 40x S&P 500 S&P 500 ex. Magnificent 7 35x NTM PE Ratio 30x 30x 25x 21x 20x 19x 15x 10x 5x 0x 2009 2014 2019 2023 Past performance is not a r
Slide 8: A Closer Look At Mag Valuations
A Closer Look At Mag 7 Valuations As of 31 March 2024 3-5 year Earnings Growth Expectations Price to Earnings Growth Ratio NTM compared with Price Earnings Multiple 35% R1000G ex Mag 7 1.66 NVIDIA 30% NVIDIA 1.14 Meta Amazon Platforms Meta Platforms 0.92 25% Est. 3-5 EPS Growth Amazon 1.39 20% Alpha
Slide 9: S&P500 earnings improvement broadens out later in 2024
S&P500 earnings improvement broadens out later in 2024 As at 4 April 2024 S&P 500 EPS Growth % Deceleration Earnings Recession Recovery 14.2 10.3 Market rally begins 10.5 10.1 7.4 8.8 5.8 3.3 4.0 -1.5 -0.9 -3.4 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23E 1Q24E 2Q24E 3Q24E 4Q24E Tech EPS Growth SP500 EP
Slide 10: Investing in AI – Monetisation becoming more important
Investing in AI – Monetisation becoming more important As of 31 December 2023 Application Owners Picks & Shovels embed AI into their existing products provide the critical equipment for or utilize it to build new products building out AI infrastructure ▪ We believe there will be winners in both buck
Slide 11: Portfolio Characteristics
Portfolio Characteristics T. R O W E P R I C E 11
Slide 12: US Large Cap Growth Equity Fund: Objective and risks
T. ROWE PRICE FUNDS SICAV - US LARGE CAP GROWTH EQUITY FUND Objective and risks Objective To increase the value of its shares, over the long term, through growth in the value of its investments. Investment Process The fund is actively managed and invests mainly in a diversified portfolio of shares f
Slide 13: T. Rowe Price Funds SICAV—US Large Cap Growth Equity Fund
T. Rowe Price Funds SICAV—US Large Cap Growth Equity Fund As of 31 December 2023 Innovation and ▪ Russell 1000 Growth net disruption investing 30% Index benchmark 1 in uncertainty: In growth investing, Generate insights on free cash flow and its ▪ 60-75 issuers growth are the single future winners t
Slide 14: Largest Over/Underweights
10 Largest Over/Underweights As of 31 March 2024 T. Rowe Price Funds SICAV—US Large Cap Growth Equity Fund Overweights Underweights % of % of % of % of Portfolio Index Difference Portfolio Index Difference Fiserv 3.0% 0.1% 2.9% Microsoft 9.7% 12.1% (2.4)% Intuit 3.2 0.7 2.5 Broadcom 0.0 2.2 (2.2) Ci
Slide 15: Select Themes and Exposures within US Large-cap Growth
Select Themes and Exposures within US Large-cap Growth T. Rowe Price Funds SICAV—US Large Cap Growth Equity Fund Top 10 positions % of Industry Modestly more Durable growth as at 31 March 2024 Fund defensive exposure In 2024 mostly on Achieved through MICROSOFT Software 9.7 individual stock level la
Slide 16: Relative Alpha Contribution Outside Magnificent 7
Relative Alpha Contribution Outside Magnificent 7 From 31 December 2022 through 31 March 2024 % Contribution to Alpha SICAV LCG vs Russell 1000 Growth 31 Dec 2022 through 31 Mar 2024 (Cumulative, Gross): +965bpts Contribution to Return % of Relative Company (bps) Outperformance Meta 201 21% Nvidia 8
Slide 17: Schlumberger (SLB)
Schlumberger (SLB) As of 31 March 2024 A technology-focused leader in the provision of oilfield services Unmatched, global scale and a leader in technology and performance. SLB is typically the first call when developing Competitive complex reservoirs. Advantages Well-positioned to potentially benef
Slide 18: Stryker (SYK)
Stryker (SYK) As of 31 March 2024 An innovative medical device business, with diverse end markets Innovative leadership, a strong salesforce culture, robust end- market growth, and high switching costs. Management are Competitive effective capital allocators with a strong track record in accretive M
Slide 19: Fiserv (FI)
Fiserv (FI) As of 31 March 2024 A well-run, global leader in fintech and payments Attractive financial model supported by recurring revenue, high retention rates, and high incremental margins. Excellent Competitive management execution through cycles. Advantages Fiserv’s two key products continue to
Slide 20: Amphenol (APH)
Amphenol (APH) As of 31 March 2024 An underappreciated way to play the AI theme – wires! Industry leader in connectors and leads serving the industrial, aerospace and automotive markets and now with an additional market in building out infrastructure of high- Competitive performance datacenters inco
Slide 21: US All-Cap Opportunities Investment Team
US All-Cap Opportunities Investment Team As of 31 December 2023 Manager Justin P. White Portfolio Manager Strategy inception date September 1985 Justin White, CFA ▪ 15 years of investment experience Portfolio Manager inception date April 2016 ▪ 15 years with T. Rowe Price ▪ A.B., Dartmouth College B
Slide 22: US All-Cap Opportunities Equity Fund: Objective and risks
T. ROWE PRICE FUNDS SICAV - US ALL-CAP OPPORTUNITIES EQUITY FUND Objective and risks Objective The US All-Cap Opportunities Equity Composite seeks to provide long-term growth of capital by investing primarily in the common stocks of companies operating in sectors T. Rowe Price believes will be the f
Slide 23: All-Cap Opportunities Fund vs Russell 3000 Index
All-Cap Opportunities Fund vs RUSSELL 3000 index1 Figures calculated in U.S. Dollars Rolling periods from Since Manager Inception 1 Apr 2016 through 31 December 2023 1-YEAR ROLLING PERFORMANCE 3-YEAR ROLLING PERFORMANCE 5-YEAR ROLLING PERFORMANCE 80 80 80 Outperforming Outperforming Outperforming Al
Slide 24: Appendix
Appendix T. R O W E P R I C E 24
Slide 25: Portfolio Snapshot
Portfolio Snapshot T. Rowe Price Funds SICAV—US Large Cap Growth Equity Fund As of 31 December 2023 Sector Diversification Percent 50 T. Rowe Price Funds SICAV—US Large Cap Growth Equity Fund 40 Russell 1000 Growth Index Net 30% Withholding TaxɎ 30 Difference 20 10 0 -10 Health Care Financials
Slide 26: Performance
Performance T. Rowe Price Funds SICAV—US Large Cap Growth Equity Fund Periods Ended 31 March 2024 Figures are Calculated in U.S. Dollars Annualised Since Manager Since Three One Three Five Seven Inception Ten Fifteen Twenty Inception Months Year$ Years Years Years 1 Jan 2017 Years Years Years 31 Jul
Slide 27: Performance
Performance T. Rowe Price Funds SICAV—US Large Cap Growth Equity Fund Periods Ended 31 December 2023 Figures are Calculated in U.S. Dollars Calendar Years 2003‡ 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023$ US Large-Cap Growth Equity Fund – 12.8
Slide 28: Performance
Performance As of 31 March 2024. Figures are Calculated in Great British Pound T. Rowe Price Funds OEIC—US Large Cap Growth Equity Fund Annualised One Three Five Year-to-Date Year Years Years OEIC US Large Cap Growth Equity Fund - Class C (GBP)† 24.33% 44.42% 12.02% 16.17% OEIC US Large Cap Growth E
Slide 29: Attribution Analysis (USD)—Major Impacts
Attribution Analysis (USD)—Major Impacts T. Rowe Price Funds SICAV—US Large Cap Growth Equity Fund vs. Russell 1000 Growth Index One Year Ended 31 December 2023 By Sector (%) 8.00 Value Added - Percentage 6.00 Total Value Added Value Added From 4.00 Sector Weight 2.00 Value Added From Stock Selectio
Slide 30: Performance—Risk Return Characteristics
Performance—Risk Return Characteristics Since Inception Ended 31 December 2023 Figures are Calculated in U.S. Dollars ■ T. Rowe Price Funds SICAV—US Large Cap Growth Equity Fund Class I Since Inception₸ ■ Russell 1000 Growth Index Net 30% Withholding Tax∆Ɏ T. Rowe Price 13 Funds SICAV—US Russell 100
Slide 31: Performance
Performance As of 31 March 2024. Figures are Calculated in Great British Pound T. Rowe Price Funds OEIC—US All-Cap Opportunities Equity Fund Annusalised Since Year-to- One Inception Date Year 7 June 2022 OEIC US All-Cap Opportunities Equity Fund - Class C (GBP)† 14.35% 35.88% 19.58 OEIC US All-Cap O
Slide 32: Additional Information
Additional Information MSCI. The MSCI data is comprised of a custom index calculated by MSCI for, and as requested by, T. Rowe Price. The MSCI data is for internal use only and may not be redistributed or used in connection with creating or offering any securities, financial products, or indices. Ne
Slide 33: Important Information
Important Information This material is being furnished for general informational and/or marketing purposes only. The material does not constitute or undertake to give advice of any nature, including fiduciary investment advice, nor is it intended to serve as the primary basis for an investment decis
Slide 34: Thank You
D4 T.RowePrice Thank You